Associated Genetic Biomarkers
PIK3C2B Amplification is present in 0.41% of AACR GENIE cases, with conventional glioblastoma multiforme, glioblastoma, and breast invasive ductal carcinoma having the greatest prevalence .
PIK3C2B Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2B Amplification as an inclusion criterion, 1 is early phase 1 (1 open).
Trials with PIK3C2B Amplification in the inclusion eligibility criteria most commonly target malignant glioma .
Everolimus and ribociclib are the most frequent therapies in trials with PIK3C2B Amplification as an inclusion criteria .
Significance of PIK3C2B Amplification in Diseases
Malignant Glioma +
PIK3C2B is altered in 6.76% of malignant glioma patients with PIK3C2B Amplification present in 4.15% of all malignant glioma patients .
PIK3C2B Amplification is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2B Amplification and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.